nodes	percent_of_prediction	percent_of_DWPC	metapath
Icatibant—ANPEP—hematologic cancer	0.765	1	CbGaD
Icatibant—ANPEP—hematopoietic system—hematologic cancer	0.00492	0.159	CbGeAlD
Icatibant—BDKRB2—lung—hematologic cancer	0.00458	0.148	CbGeAlD
Icatibant—BDKRB2—testis—hematologic cancer	0.00432	0.14	CbGeAlD
Icatibant—ANPEP—blood—hematologic cancer	0.00326	0.106	CbGeAlD
Icatibant—ANPEP—bone marrow—hematologic cancer	0.00315	0.102	CbGeAlD
Icatibant—BDKRB2—lymph node—hematologic cancer	0.00313	0.101	CbGeAlD
Icatibant—ANPEP—lung—hematologic cancer	0.00286	0.0925	CbGeAlD
Icatibant—ANPEP—testis—hematologic cancer	0.00269	0.0873	CbGeAlD
Icatibant—ANPEP—lymph node—hematologic cancer	0.00195	0.0633	CbGeAlD
Icatibant—Anaphylactic shock—Vinorelbine—hematologic cancer	0.000266	0.00331	CcSEcCtD
Icatibant—Nausea—Pentostatin—hematologic cancer	0.000265	0.00331	CcSEcCtD
Icatibant—Nausea—Anagrelide—hematologic cancer	0.000265	0.00331	CcSEcCtD
Icatibant—Rash—Teniposide—hematologic cancer	0.000264	0.0033	CcSEcCtD
Icatibant—Dermatitis—Teniposide—hematologic cancer	0.000264	0.00329	CcSEcCtD
Icatibant—Body temperature increased—Cladribine—hematologic cancer	0.000264	0.00329	CcSEcCtD
Icatibant—Injection site reaction—Doxorubicin—hematologic cancer	0.000263	0.00329	CcSEcCtD
Icatibant—Headache—Teniposide—hematologic cancer	0.000263	0.00327	CcSEcCtD
Icatibant—Nervous system disorder—Vinorelbine—hematologic cancer	0.000261	0.00325	CcSEcCtD
Icatibant—Hypersensitivity—Chlorambucil—hematologic cancer	0.000257	0.00321	CcSEcCtD
Icatibant—Dizziness—Busulfan—hematologic cancer	0.000257	0.0032	CcSEcCtD
Icatibant—Nausea—Idarubicin—hematologic cancer	0.000256	0.00319	CcSEcCtD
Icatibant—Hypersensitivity—Nilotinib—hematologic cancer	0.000251	0.00314	CcSEcCtD
Icatibant—Hypersensitivity—Imatinib—hematologic cancer	0.00025	0.00312	CcSEcCtD
Icatibant—Dizziness—Procarbazine—hematologic cancer	0.000249	0.00311	CcSEcCtD
Icatibant—Nausea—Teniposide—hematologic cancer	0.000249	0.0031	CcSEcCtD
Icatibant—Nervous system disorder—Thiotepa—hematologic cancer	0.000249	0.0031	CcSEcCtD
Icatibant—Hypersensitivity—Cladribine—hematologic cancer	0.000246	0.00306	CcSEcCtD
Icatibant—Rash—Busulfan—hematologic cancer	0.000245	0.00305	CcSEcCtD
Icatibant—Dermatitis—Busulfan—hematologic cancer	0.000245	0.00305	CcSEcCtD
Icatibant—Dizziness—Dasatinib—hematologic cancer	0.000244	0.00305	CcSEcCtD
Icatibant—Dizziness—Bexarotene—hematologic cancer	0.000244	0.00305	CcSEcCtD
Icatibant—Headache—Busulfan—hematologic cancer	0.000243	0.00303	CcSEcCtD
Icatibant—Nervous system disorder—Thalidomide—hematologic cancer	0.000241	0.003	CcSEcCtD
Icatibant—Rash—Procarbazine—hematologic cancer	0.000238	0.00296	CcSEcCtD
Icatibant—Dermatitis—Procarbazine—hematologic cancer	0.000237	0.00296	CcSEcCtD
Icatibant—Headache—Procarbazine—hematologic cancer	0.000236	0.00294	CcSEcCtD
Icatibant—Hypersensitivity—Vinblastine—hematologic cancer	0.000236	0.00294	CcSEcCtD
Icatibant—Body temperature increased—Lenalidomide—hematologic cancer	0.000234	0.00292	CcSEcCtD
Icatibant—Anaphylactic shock—Alitretinoin—hematologic cancer	0.000234	0.00291	CcSEcCtD
Icatibant—Rash—Bexarotene—hematologic cancer	0.000233	0.0029	CcSEcCtD
Icatibant—Rash—Dasatinib—hematologic cancer	0.000233	0.0029	CcSEcCtD
Icatibant—Dermatitis—Dasatinib—hematologic cancer	0.000233	0.0029	CcSEcCtD
Icatibant—Dermatitis—Bexarotene—hematologic cancer	0.000233	0.0029	CcSEcCtD
Icatibant—Rash—Fludarabine—hematologic cancer	0.000232	0.0029	CcSEcCtD
Icatibant—Dermatitis—Fludarabine—hematologic cancer	0.000232	0.00289	CcSEcCtD
Icatibant—Headache—Bexarotene—hematologic cancer	0.000231	0.00289	CcSEcCtD
Icatibant—Headache—Dasatinib—hematologic cancer	0.000231	0.00289	CcSEcCtD
Icatibant—Anaphylactic shock—Ifosfamide—hematologic cancer	0.000231	0.00288	CcSEcCtD
Icatibant—Headache—Fludarabine—hematologic cancer	0.000231	0.00288	CcSEcCtD
Icatibant—Nausea—Busulfan—hematologic cancer	0.000231	0.00288	CcSEcCtD
Icatibant—Body temperature increased—Hydroxyurea—hematologic cancer	0.000231	0.00287	CcSEcCtD
Icatibant—Nervous system disorder—Alitretinoin—hematologic cancer	0.000229	0.00286	CcSEcCtD
Icatibant—Nervous system disorder—Ifosfamide—hematologic cancer	0.000226	0.00282	CcSEcCtD
Icatibant—Dizziness—Nilotinib—hematologic cancer	0.000226	0.00281	CcSEcCtD
Icatibant—Anaphylactic shock—Vincristine—hematologic cancer	0.000225	0.00281	CcSEcCtD
Icatibant—Dizziness—Imatinib—hematologic cancer	0.000224	0.0028	CcSEcCtD
Icatibant—Hypersensitivity—Melphalan—hematologic cancer	0.000224	0.00279	CcSEcCtD
Icatibant—Nausea—Procarbazine—hematologic cancer	0.000224	0.00279	CcSEcCtD
Icatibant—Nervous system disorder—Vincristine—hematologic cancer	0.000221	0.00275	CcSEcCtD
Icatibant—Dizziness—Cladribine—hematologic cancer	0.00022	0.00275	CcSEcCtD
Icatibant—Nausea—Bexarotene—hematologic cancer	0.000219	0.00274	CcSEcCtD
Icatibant—Nausea—Dasatinib—hematologic cancer	0.000219	0.00274	CcSEcCtD
Icatibant—Anaphylactic shock—Mitoxantrone—hematologic cancer	0.000219	0.00273	CcSEcCtD
Icatibant—Anaphylactic shock—Irinotecan—hematologic cancer	0.000219	0.00273	CcSEcCtD
Icatibant—Nausea—Fludarabine—hematologic cancer	0.000219	0.00273	CcSEcCtD
Icatibant—Hypersensitivity—Lenalidomide—hematologic cancer	0.000218	0.00272	CcSEcCtD
Icatibant—Rash—Nilotinib—hematologic cancer	0.000215	0.00268	CcSEcCtD
Icatibant—Body temperature increased—Bortezomib—hematologic cancer	0.000215	0.00268	CcSEcCtD
Icatibant—Dermatitis—Nilotinib—hematologic cancer	0.000215	0.00268	CcSEcCtD
Icatibant—Nervous system disorder—Irinotecan—hematologic cancer	0.000215	0.00268	CcSEcCtD
Icatibant—Hypersensitivity—Hydroxyurea—hematologic cancer	0.000215	0.00268	CcSEcCtD
Icatibant—Rash—Imatinib—hematologic cancer	0.000214	0.00267	CcSEcCtD
Icatibant—Headache—Nilotinib—hematologic cancer	0.000214	0.00267	CcSEcCtD
Icatibant—Dermatitis—Imatinib—hematologic cancer	0.000214	0.00267	CcSEcCtD
Icatibant—Body temperature increased—Bleomycin—hematologic cancer	0.000213	0.00266	CcSEcCtD
Icatibant—Anaphylactic shock—Gemcitabine—hematologic cancer	0.000213	0.00266	CcSEcCtD
Icatibant—Headache—Imatinib—hematologic cancer	0.000213	0.00265	CcSEcCtD
Icatibant—Dizziness—Vinblastine—hematologic cancer	0.000211	0.00264	CcSEcCtD
Icatibant—Rash—Cladribine—hematologic cancer	0.00021	0.00262	CcSEcCtD
Icatibant—Body temperature increased—Vinorelbine—hematologic cancer	0.00021	0.00262	CcSEcCtD
Icatibant—Dermatitis—Cladribine—hematologic cancer	0.00021	0.00262	CcSEcCtD
Icatibant—Nervous system disorder—Gemcitabine—hematologic cancer	0.000209	0.00261	CcSEcCtD
Icatibant—Headache—Cladribine—hematologic cancer	0.000209	0.0026	CcSEcCtD
Icatibant—Nausea—Chlorambucil—hematologic cancer	0.000207	0.00258	CcSEcCtD
Icatibant—Nausea—Nilotinib—hematologic cancer	0.000203	0.00253	CcSEcCtD
Icatibant—Nausea—Imatinib—hematologic cancer	0.000202	0.00251	CcSEcCtD
Icatibant—Body temperature increased—Thiotepa—hematologic cancer	0.000201	0.0025	CcSEcCtD
Icatibant—Hypersensitivity—Bortezomib—hematologic cancer	0.000201	0.0025	CcSEcCtD
Icatibant—Headache—Vinblastine—hematologic cancer	0.0002	0.0025	CcSEcCtD
Icatibant—Anaphylactic shock—Cisplatin—hematologic cancer	0.000199	0.00248	CcSEcCtD
Icatibant—Hypersensitivity—Bleomycin—hematologic cancer	0.000199	0.00248	CcSEcCtD
Icatibant—Nausea—Cladribine—hematologic cancer	0.000198	0.00247	CcSEcCtD
Icatibant—Hypersensitivity—Vinorelbine—hematologic cancer	0.000196	0.00244	CcSEcCtD
Icatibant—Dizziness—Lenalidomide—hematologic cancer	0.000196	0.00244	CcSEcCtD
Icatibant—Nervous system disorder—Cisplatin—hematologic cancer	0.000195	0.00243	CcSEcCtD
Icatibant—Body temperature increased—Thalidomide—hematologic cancer	0.000194	0.00242	CcSEcCtD
Icatibant—Dizziness—Hydroxyurea—hematologic cancer	0.000193	0.0024	CcSEcCtD
Icatibant—Rash—Melphalan—hematologic cancer	0.000192	0.00239	CcSEcCtD
Icatibant—Dermatitis—Melphalan—hematologic cancer	0.000192	0.00239	CcSEcCtD
Icatibant—Nausea—Vinblastine—hematologic cancer	0.00019	0.00237	CcSEcCtD
Icatibant—Hypersensitivity—Thiotepa—hematologic cancer	0.000187	0.00233	CcSEcCtD
Icatibant—Rash—Lenalidomide—hematologic cancer	0.000186	0.00233	CcSEcCtD
Icatibant—Body temperature increased—Carmustine—hematologic cancer	0.000186	0.00232	CcSEcCtD
Icatibant—Dermatitis—Lenalidomide—hematologic cancer	0.000186	0.00232	CcSEcCtD
Icatibant—Headache—Lenalidomide—hematologic cancer	0.000185	0.00231	CcSEcCtD
Icatibant—Body temperature increased—Alitretinoin—hematologic cancer	0.000185	0.0023	CcSEcCtD
Icatibant—Rash—Hydroxyurea—hematologic cancer	0.000184	0.00229	CcSEcCtD
Icatibant—Dermatitis—Hydroxyurea—hematologic cancer	0.000184	0.00229	CcSEcCtD
Icatibant—Headache—Hydroxyurea—hematologic cancer	0.000183	0.00228	CcSEcCtD
Icatibant—Body temperature increased—Ifosfamide—hematologic cancer	0.000182	0.00228	CcSEcCtD
Icatibant—Anaphylactic shock—Etoposide—hematologic cancer	0.000182	0.00227	CcSEcCtD
Icatibant—Hypersensitivity—Thalidomide—hematologic cancer	0.000181	0.00226	CcSEcCtD
Icatibant—Nausea—Melphalan—hematologic cancer	0.000181	0.00225	CcSEcCtD
Icatibant—Dizziness—Bortezomib—hematologic cancer	0.00018	0.00224	CcSEcCtD
Icatibant—Anaphylactic shock—Prednisolone—hematologic cancer	0.00018	0.00224	CcSEcCtD
Icatibant—Body temperature increased—Vincristine—hematologic cancer	0.000178	0.00222	CcSEcCtD
Icatibant—Dizziness—Vinorelbine—hematologic cancer	0.000176	0.00219	CcSEcCtD
Icatibant—Nausea—Lenalidomide—hematologic cancer	0.000176	0.00219	CcSEcCtD
Icatibant—Hypersensitivity—Carmustine—hematologic cancer	0.000174	0.00217	CcSEcCtD
Icatibant—Body temperature increased—Mitoxantrone—hematologic cancer	0.000173	0.00216	CcSEcCtD
Icatibant—Body temperature increased—Irinotecan—hematologic cancer	0.000173	0.00216	CcSEcCtD
Icatibant—Nausea—Hydroxyurea—hematologic cancer	0.000173	0.00216	CcSEcCtD
Icatibant—Hypersensitivity—Alitretinoin—hematologic cancer	0.000172	0.00215	CcSEcCtD
Icatibant—Rash—Bortezomib—hematologic cancer	0.000172	0.00214	CcSEcCtD
Icatibant—Dermatitis—Bortezomib—hematologic cancer	0.000171	0.00214	CcSEcCtD
Icatibant—Headache—Bortezomib—hematologic cancer	0.00017	0.00213	CcSEcCtD
Icatibant—Rash—Bleomycin—hematologic cancer	0.00017	0.00212	CcSEcCtD
Icatibant—Dermatitis—Bleomycin—hematologic cancer	0.00017	0.00212	CcSEcCtD
Icatibant—Hypersensitivity—Ifosfamide—hematologic cancer	0.00017	0.00212	CcSEcCtD
Icatibant—Body temperature increased—Gemcitabine—hematologic cancer	0.000169	0.0021	CcSEcCtD
Icatibant—Dizziness—Thiotepa—hematologic cancer	0.000168	0.00209	CcSEcCtD
Icatibant—Rash—Vinorelbine—hematologic cancer	0.000168	0.00209	CcSEcCtD
Icatibant—Dermatitis—Vinorelbine—hematologic cancer	0.000167	0.00209	CcSEcCtD
Icatibant—Headache—Vinorelbine—hematologic cancer	0.000166	0.00208	CcSEcCtD
Icatibant—Hypersensitivity—Vincristine—hematologic cancer	0.000166	0.00207	CcSEcCtD
Icatibant—Anaphylactic shock—Triamcinolone—hematologic cancer	0.000165	0.00206	CcSEcCtD
Icatibant—Dizziness—Thalidomide—hematologic cancer	0.000162	0.00202	CcSEcCtD
Icatibant—Nausea—Bortezomib—hematologic cancer	0.000162	0.00202	CcSEcCtD
Icatibant—Hypersensitivity—Irinotecan—hematologic cancer	0.000161	0.00201	CcSEcCtD
Icatibant—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000161	0.00201	CcSEcCtD
Icatibant—ANPEP—C-MYB transcription factor network—KRAS—hematologic cancer	0.000161	0.0013	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CD—hematologic cancer	0.000161	0.0013	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—CCL3—hematologic cancer	0.000161	0.0013	CbGpPWpGaD
Icatibant—Nausea—Bleomycin—hematologic cancer	0.00016	0.002	CcSEcCtD
Icatibant—Rash—Thiotepa—hematologic cancer	0.00016	0.002	CcSEcCtD
Icatibant—Dermatitis—Thiotepa—hematologic cancer	0.00016	0.00199	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—PTHLH—hematologic cancer	0.00016	0.00128	CbGpPWpGaD
Icatibant—Headache—Thiotepa—hematologic cancer	0.000159	0.00198	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—SPHK1—hematologic cancer	0.000158	0.00128	CbGpPWpGaD
Icatibant—Nausea—Vinorelbine—hematologic cancer	0.000158	0.00197	CcSEcCtD
Icatibant—Body temperature increased—Cisplatin—hematologic cancer	0.000157	0.00196	CcSEcCtD
Icatibant—Dizziness—Carmustine—hematologic cancer	0.000156	0.00194	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—PTGER4—hematologic cancer	0.000155	0.00125	CbGpPWpGaD
Icatibant—Rash—Thalidomide—hematologic cancer	0.000155	0.00193	CcSEcCtD
Icatibant—Dermatitis—Thalidomide—hematologic cancer	0.000155	0.00193	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—FGF2—hematologic cancer	0.000155	0.00124	CbGpPWpGaD
Icatibant—Dizziness—Alitretinoin—hematologic cancer	0.000154	0.00193	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—BCL2—hematologic cancer	0.000154	0.00124	CbGpPWpGaD
Icatibant—Headache—Thalidomide—hematologic cancer	0.000154	0.00192	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—IFT172—hematologic cancer	0.000154	0.00124	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—ARHGEF12—hematologic cancer	0.000153	0.00123	CbGpPWpGaD
Icatibant—Dizziness—Ifosfamide—hematologic cancer	0.000153	0.0019	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3R1—hematologic cancer	0.000152	0.00123	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—MDM2—hematologic cancer	0.000152	0.00122	CbGpPWpGaD
Icatibant—Nausea—Thiotepa—hematologic cancer	0.000151	0.00188	CcSEcCtD
Icatibant—Anaphylactic shock—Dexamethasone—hematologic cancer	0.00015	0.00187	CcSEcCtD
Icatibant—Anaphylactic shock—Betamethasone—hematologic cancer	0.00015	0.00187	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—ARHGEF1—hematologic cancer	0.000149	0.0012	CbGpPWpGaD
Icatibant—Dizziness—Vincristine—hematologic cancer	0.000149	0.00186	CcSEcCtD
Icatibant—Rash—Carmustine—hematologic cancer	0.000149	0.00185	CcSEcCtD
Icatibant—Dermatitis—Carmustine—hematologic cancer	0.000148	0.00185	CcSEcCtD
Icatibant—Headache—Carmustine—hematologic cancer	0.000148	0.00184	CcSEcCtD
Icatibant—Rash—Alitretinoin—hematologic cancer	0.000147	0.00184	CcSEcCtD
Icatibant—Nervous system disorder—Betamethasone—hematologic cancer	0.000147	0.00183	CcSEcCtD
Icatibant—Nervous system disorder—Dexamethasone—hematologic cancer	0.000147	0.00183	CcSEcCtD
Icatibant—Dermatitis—Alitretinoin—hematologic cancer	0.000147	0.00183	CcSEcCtD
Icatibant—Hypersensitivity—Cisplatin—hematologic cancer	0.000147	0.00183	CcSEcCtD
Icatibant—Headache—Alitretinoin—hematologic cancer	0.000146	0.00182	CcSEcCtD
Icatibant—Nausea—Thalidomide—hematologic cancer	0.000146	0.00182	CcSEcCtD
Icatibant—Rash—Ifosfamide—hematologic cancer	0.000146	0.00181	CcSEcCtD
Icatibant—Dermatitis—Ifosfamide—hematologic cancer	0.000145	0.00181	CcSEcCtD
Icatibant—Dizziness—Irinotecan—hematologic cancer	0.000145	0.00181	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—CXCR5—hematologic cancer	0.000145	0.00117	CbGpPWpGaD
Icatibant—Body temperature increased—Etoposide—hematologic cancer	0.000144	0.0018	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—RPS14—hematologic cancer	0.000142	0.00114	CbGpPWpGaD
Icatibant—Rash—Vincristine—hematologic cancer	0.000142	0.00177	CcSEcCtD
Icatibant—Dermatitis—Vincristine—hematologic cancer	0.000142	0.00177	CcSEcCtD
Icatibant—Headache—Vincristine—hematologic cancer	0.000141	0.00176	CcSEcCtD
Icatibant—BDKRB2—Peptide ligand-binding receptors—CCL2—hematologic cancer	0.000141	0.00113	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CB—hematologic cancer	0.000141	0.00113	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PPEF1—hematologic cancer	0.000141	0.00113	CbGpPWpGaD
Icatibant—Nausea—Carmustine—hematologic cancer	0.00014	0.00175	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—GNA13—hematologic cancer	0.00014	0.00113	CbGpPWpGaD
Icatibant—Nausea—Alitretinoin—hematologic cancer	0.000139	0.00173	CcSEcCtD
Icatibant—Rash—Irinotecan—hematologic cancer	0.000138	0.00172	CcSEcCtD
Icatibant—Rash—Mitoxantrone—hematologic cancer	0.000138	0.00172	CcSEcCtD
Icatibant—Dermatitis—Irinotecan—hematologic cancer	0.000138	0.00172	CcSEcCtD
Icatibant—Dermatitis—Mitoxantrone—hematologic cancer	0.000138	0.00172	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—TIAM1—hematologic cancer	0.000138	0.00111	CbGpPWpGaD
Icatibant—Headache—Mitoxantrone—hematologic cancer	0.000137	0.00171	CcSEcCtD
Icatibant—Headache—Irinotecan—hematologic cancer	0.000137	0.00171	CcSEcCtD
Icatibant—ANPEP—C-MYB transcription factor network—HRAS—hematologic cancer	0.000137	0.0011	CbGpPWpGaD
Icatibant—BDKRB2—GPCR ligand binding—CXCR4—hematologic cancer	0.000137	0.0011	CbGpPWpGaD
Icatibant—Nausea—Ifosfamide—hematologic cancer	0.000137	0.00171	CcSEcCtD
Icatibant—Rash—Gemcitabine—hematologic cancer	0.000135	0.00168	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—hematologic cancer	0.000134	0.00108	CbGpPWpGaD
Icatibant—Dermatitis—Gemcitabine—hematologic cancer	0.000134	0.00168	CcSEcCtD
Icatibant—Hypersensitivity—Etoposide—hematologic cancer	0.000134	0.00167	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—CCL17—hematologic cancer	0.000134	0.00108	CbGpPWpGaD
Icatibant—Headache—Gemcitabine—hematologic cancer	0.000134	0.00167	CcSEcCtD
Icatibant—Nausea—Vincristine—hematologic cancer	0.000134	0.00167	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—JAK3—hematologic cancer	0.000133	0.00107	CbGpPWpGaD
Icatibant—Hypersensitivity—Prednisolone—hematologic cancer	0.000132	0.00165	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—JUN—hematologic cancer	0.000132	0.00106	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CXCR5—hematologic cancer	0.000132	0.00106	CbGpPWpGaD
Icatibant—Body temperature increased—Triamcinolone—hematologic cancer	0.000131	0.00163	CcSEcCtD
Icatibant—Anaphylactic shock—Prednisone—hematologic cancer	0.000131	0.00163	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—hematologic cancer	0.00013	0.00105	CbGpPWpGaD
Icatibant—Nausea—Mitoxantrone—hematologic cancer	0.00013	0.00162	CcSEcCtD
Icatibant—Nausea—Irinotecan—hematologic cancer	0.00013	0.00162	CcSEcCtD
Icatibant—Nervous system disorder—Prednisone—hematologic cancer	0.000128	0.0016	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—CDKN1A—hematologic cancer	0.000128	0.00103	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—CCR7—hematologic cancer	0.000128	0.00103	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—CXCL13—hematologic cancer	0.000128	0.00103	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—PTEN—hematologic cancer	0.000128	0.00103	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—hematologic cancer	0.000127	0.00102	CbGpPWpGaD
Icatibant—BDKRB2—G alpha (q) signalling events—PIK3R1—hematologic cancer	0.000127	0.00102	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—GNA13—hematologic cancer	0.000127	0.00102	CbGpPWpGaD
Icatibant—Nausea—Gemcitabine—hematologic cancer	0.000127	0.00158	CcSEcCtD
Icatibant—Rash—Cisplatin—hematologic cancer	0.000125	0.00156	CcSEcCtD
Icatibant—Dermatitis—Cisplatin—hematologic cancer	0.000125	0.00156	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—TIAM1—hematologic cancer	0.000125	0.00101	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—IL3RA—hematologic cancer	0.000125	0.001	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—EIF4EBP1—hematologic cancer	0.000124	0.000999	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—EP300—hematologic cancer	0.000122	0.000981	CbGpPWpGaD
Icatibant—Hypersensitivity—Triamcinolone—hematologic cancer	0.000122	0.00152	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—JAK3—hematologic cancer	0.000121	0.000976	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—hematologic cancer	0.000121	0.000975	CbGpPWpGaD
Icatibant—Dizziness—Etoposide—hematologic cancer	0.000121	0.0015	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—RGS2—hematologic cancer	0.00012	0.000968	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—TRH—hematologic cancer	0.000119	0.000957	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—TRIO—hematologic cancer	0.000119	0.000957	CbGpPWpGaD
Icatibant—Dizziness—Prednisolone—hematologic cancer	0.000119	0.00148	CcSEcCtD
Icatibant—Body temperature increased—Dexamethasone—hematologic cancer	0.000119	0.00148	CcSEcCtD
Icatibant—Body temperature increased—Betamethasone—hematologic cancer	0.000119	0.00148	CcSEcCtD
Icatibant—Nausea—Cisplatin—hematologic cancer	0.000118	0.00147	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—CXCL13—hematologic cancer	0.000116	0.000935	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CCR7—hematologic cancer	0.000116	0.000935	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—LPAR1—hematologic cancer	0.000115	0.000927	CbGpPWpGaD
Icatibant—Rash—Etoposide—hematologic cancer	0.000115	0.00143	CcSEcCtD
Icatibant—Dermatitis—Etoposide—hematologic cancer	0.000115	0.00143	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—HSPA5—hematologic cancer	0.000115	0.000924	CbGpPWpGaD
Icatibant—Headache—Etoposide—hematologic cancer	0.000114	0.00142	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—hematologic cancer	0.000114	0.000915	CbGpPWpGaD
Icatibant—Rash—Prednisolone—hematologic cancer	0.000113	0.00141	CcSEcCtD
Icatibant—Dermatitis—Prednisolone—hematologic cancer	0.000113	0.00141	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—IL3RA—hematologic cancer	0.000113	0.000911	CbGpPWpGaD
Icatibant—Headache—Prednisolone—hematologic cancer	0.000113	0.0014	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—CALR—hematologic cancer	0.000111	0.000895	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HDAC11—hematologic cancer	0.000111	0.000894	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—hematologic cancer	0.00011	0.000889	CbGpPWpGaD
Icatibant—Dizziness—Triamcinolone—hematologic cancer	0.000109	0.00136	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—RGS2—hematologic cancer	0.000109	0.000879	CbGpPWpGaD
Icatibant—Anaphylactic shock—Methotrexate—hematologic cancer	0.000109	0.00136	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—NRAS—hematologic cancer	0.000108	0.000873	CbGpPWpGaD
Icatibant—Nausea—Etoposide—hematologic cancer	0.000108	0.00135	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—TRIO—hematologic cancer	0.000108	0.000869	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—TRH—hematologic cancer	0.000108	0.000869	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—FBXW7—hematologic cancer	0.000108	0.000866	CbGpPWpGaD
Icatibant—Nervous system disorder—Methotrexate—hematologic cancer	0.000107	0.00134	CcSEcCtD
Icatibant—Nausea—Prednisolone—hematologic cancer	0.000107	0.00133	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—BCR—hematologic cancer	0.000107	0.000857	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PDE4B—hematologic cancer	0.000106	0.000853	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—CNR2—hematologic cancer	0.000106	0.000853	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—LPAR1—hematologic cancer	0.000105	0.000842	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—RAC2—hematologic cancer	0.000104	0.00084	CbGpPWpGaD
Icatibant—Rash—Triamcinolone—hematologic cancer	0.000104	0.0013	CcSEcCtD
Icatibant—Dermatitis—Triamcinolone—hematologic cancer	0.000104	0.0013	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—MAPK3—hematologic cancer	0.000104	0.000836	CbGpPWpGaD
Icatibant—Headache—Triamcinolone—hematologic cancer	0.000104	0.00129	CcSEcCtD
Icatibant—Body temperature increased—Prednisone—hematologic cancer	0.000103	0.00129	CcSEcCtD
Icatibant—Anaphylactic shock—Epirubicin—hematologic cancer	0.000102	0.00127	CcSEcCtD
Icatibant—Nervous system disorder—Epirubicin—hematologic cancer	0.0001	0.00125	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—ADCY7—hematologic cancer	9.97e-05	0.000802	CbGpPWpGaD
Icatibant—Dizziness—Dexamethasone—hematologic cancer	9.92e-05	0.00124	CcSEcCtD
Icatibant—Dizziness—Betamethasone—hematologic cancer	9.92e-05	0.00124	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—HDAC10—hematologic cancer	9.9e-05	0.000797	CbGpPWpGaD
Icatibant—Nausea—Triamcinolone—hematologic cancer	9.82e-05	0.00122	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—CNR2—hematologic cancer	9.63e-05	0.000775	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PDE4B—hematologic cancer	9.63e-05	0.000775	CbGpPWpGaD
Icatibant—Hypersensitivity—Prednisone—hematologic cancer	9.63e-05	0.0012	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—RAC2—hematologic cancer	9.47e-05	0.000762	CbGpPWpGaD
Icatibant—Rash—Dexamethasone—hematologic cancer	9.46e-05	0.00118	CcSEcCtD
Icatibant—Rash—Betamethasone—hematologic cancer	9.46e-05	0.00118	CcSEcCtD
Icatibant—Anaphylactic shock—Doxorubicin—hematologic cancer	9.45e-05	0.00118	CcSEcCtD
Icatibant—Dermatitis—Dexamethasone—hematologic cancer	9.45e-05	0.00118	CcSEcCtD
Icatibant—Dermatitis—Betamethasone—hematologic cancer	9.45e-05	0.00118	CcSEcCtD
Icatibant—BDKRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	9.44e-05	0.00076	CbGpPWpGaD
Icatibant—Headache—Dexamethasone—hematologic cancer	9.4e-05	0.00117	CcSEcCtD
Icatibant—Headache—Betamethasone—hematologic cancer	9.4e-05	0.00117	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—KRAS—hematologic cancer	9.33e-05	0.000751	CbGpPWpGaD
Icatibant—Nervous system disorder—Doxorubicin—hematologic cancer	9.27e-05	0.00116	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—ARHGEF12—hematologic cancer	9.06e-05	0.000729	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—ADCY7—hematologic cancer	9.05e-05	0.000729	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PTHLH—hematologic cancer	9.01e-05	0.000726	CbGpPWpGaD
Icatibant—Nausea—Betamethasone—hematologic cancer	8.91e-05	0.00111	CcSEcCtD
Icatibant—Nausea—Dexamethasone—hematologic cancer	8.91e-05	0.00111	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—ARHGEF1—hematologic cancer	8.83e-05	0.00071	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PTGER4—hematologic cancer	8.78e-05	0.000706	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—TP53—hematologic cancer	8.72e-05	0.000702	CbGpPWpGaD
Icatibant—Dizziness—Prednisone—hematologic cancer	8.64e-05	0.00108	CcSEcCtD
Icatibant—Body temperature increased—Methotrexate—hematologic cancer	8.63e-05	0.00108	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CA—hematologic cancer	8.57e-05	0.00069	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CCL3—hematologic cancer	8.28e-05	0.000666	CbGpPWpGaD
Icatibant—Rash—Prednisone—hematologic cancer	8.24e-05	0.00103	CcSEcCtD
Icatibant—Dermatitis—Prednisone—hematologic cancer	8.23e-05	0.00103	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—PTHLH—hematologic cancer	8.19e-05	0.000659	CbGpPWpGaD
Icatibant—Headache—Prednisone—hematologic cancer	8.18e-05	0.00102	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—hematologic cancer	8.09e-05	0.000651	CbGpPWpGaD
Icatibant—Body temperature increased—Epirubicin—hematologic cancer	8.08e-05	0.00101	CcSEcCtD
Icatibant—Hypersensitivity—Methotrexate—hematologic cancer	8.04e-05	0.001	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—PTGER4—hematologic cancer	7.97e-05	0.000641	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—AGRN—hematologic cancer	7.92e-05	0.000637	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CCL17—hematologic cancer	7.92e-05	0.000637	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CXCR5—hematologic cancer	7.77e-05	0.000625	CbGpPWpGaD
Icatibant—Nausea—Prednisone—hematologic cancer	7.76e-05	0.000968	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—CXCR4—hematologic cancer	7.75e-05	0.000624	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—hematologic cancer	7.74e-05	0.000623	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—LEF1—hematologic cancer	7.63e-05	0.000614	CbGpPWpGaD
Icatibant—Hypersensitivity—Epirubicin—hematologic cancer	7.53e-05	0.000939	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—GNA13—hematologic cancer	7.5e-05	0.000604	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—IL3—hematologic cancer	7.47e-05	0.000602	CbGpPWpGaD
Icatibant—Body temperature increased—Doxorubicin—hematologic cancer	7.47e-05	0.000932	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—TIAM1—hematologic cancer	7.38e-05	0.000594	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—RASGRP1—hematologic cancer	7.23e-05	0.000582	CbGpPWpGaD
Icatibant—Dizziness—Methotrexate—hematologic cancer	7.22e-05	0.0009	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—CCL2—hematologic cancer	7.19e-05	0.000579	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—JAK3—hematologic cancer	7.16e-05	0.000576	CbGpPWpGaD
Icatibant—BDKRB2—G alpha (q) signalling events—PIK3CA—hematologic cancer	7.15e-05	0.000575	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CXCR4—hematologic cancer	7.04e-05	0.000567	CbGpPWpGaD
Icatibant—Hypersensitivity—Doxorubicin—hematologic cancer	6.97e-05	0.000869	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—hematologic cancer	6.96e-05	0.00056	CbGpPWpGaD
Icatibant—Rash—Methotrexate—hematologic cancer	6.88e-05	0.000859	CcSEcCtD
Icatibant—Dermatitis—Methotrexate—hematologic cancer	6.88e-05	0.000858	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—CXCL13—hematologic cancer	6.86e-05	0.000552	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CCR7—hematologic cancer	6.86e-05	0.000552	CbGpPWpGaD
Icatibant—Headache—Methotrexate—hematologic cancer	6.84e-05	0.000853	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—IL3—hematologic cancer	6.79e-05	0.000546	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—NCOR2—hematologic cancer	6.77e-05	0.000545	CbGpPWpGaD
Icatibant—Dizziness—Epirubicin—hematologic cancer	6.76e-05	0.000843	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—IL3RA—hematologic cancer	6.69e-05	0.000538	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CRKL—hematologic cancer	6.69e-05	0.000538	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—RASGRP1—hematologic cancer	6.57e-05	0.000528	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—GRB2—hematologic cancer	6.5e-05	0.000523	CbGpPWpGaD
Icatibant—Nausea—Methotrexate—hematologic cancer	6.49e-05	0.000809	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—RGS2—hematologic cancer	6.45e-05	0.000519	CbGpPWpGaD
Icatibant—Rash—Epirubicin—hematologic cancer	6.44e-05	0.000803	CcSEcCtD
Icatibant—Dermatitis—Epirubicin—hematologic cancer	6.44e-05	0.000803	CcSEcCtD
Icatibant—Headache—Epirubicin—hematologic cancer	6.4e-05	0.000798	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	6.39e-05	0.000515	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TRH—hematologic cancer	6.38e-05	0.000514	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CMA1—hematologic cancer	6.38e-05	0.000514	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TRIO—hematologic cancer	6.38e-05	0.000514	CbGpPWpGaD
Icatibant—Dizziness—Doxorubicin—hematologic cancer	6.25e-05	0.00078	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—SPHK1—hematologic cancer	6.24e-05	0.000503	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—AGO2—hematologic cancer	6.24e-05	0.000503	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—LPAR1—hematologic cancer	6.18e-05	0.000497	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HDAC9—hematologic cancer	6.18e-05	0.000497	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—H3F3B—hematologic cancer	6.12e-05	0.000492	CbGpPWpGaD
Icatibant—Nausea—Epirubicin—hematologic cancer	6.07e-05	0.000757	CcSEcCtD
Icatibant—Rash—Doxorubicin—hematologic cancer	5.96e-05	0.000743	CcSEcCtD
Icatibant—Dermatitis—Doxorubicin—hematologic cancer	5.96e-05	0.000743	CcSEcCtD
Icatibant—Headache—Doxorubicin—hematologic cancer	5.92e-05	0.000739	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	5.92e-05	0.000476	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—GRB2—hematologic cancer	5.9e-05	0.000475	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—CSF2—hematologic cancer	5.81e-05	0.000468	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PDE4B—hematologic cancer	5.69e-05	0.000458	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CNR2—hematologic cancer	5.69e-05	0.000458	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	5.66e-05	0.000456	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FGF19—hematologic cancer	5.64e-05	0.000454	CbGpPWpGaD
Icatibant—Nausea—Doxorubicin—hematologic cancer	5.62e-05	0.0007	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—PRKCG—hematologic cancer	5.61e-05	0.000451	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—JAK1—hematologic cancer	5.61e-05	0.000451	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—RAC2—hematologic cancer	5.6e-05	0.00045	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—DKK1—hematologic cancer	5.55e-05	0.000447	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—CCL2—hematologic cancer	5.53e-05	0.000445	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—STAT5B—hematologic cancer	5.51e-05	0.000443	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ADCY7—hematologic cancer	5.35e-05	0.00043	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CSF2—hematologic cancer	5.28e-05	0.000425	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—IL2RA—hematologic cancer	5.24e-05	0.000421	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—XIAP—hematologic cancer	5.2e-05	0.000419	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—JAK1—hematologic cancer	5.09e-05	0.00041	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PRKCG—hematologic cancer	5.09e-05	0.00041	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—SH2B3—hematologic cancer	5.07e-05	0.000408	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—SMARCA4—hematologic cancer	5.07e-05	0.000408	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GZMB—hematologic cancer	5.04e-05	0.000406	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CTNNA1—hematologic cancer	4.92e-05	0.000396	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—EIF4EBP1—hematologic cancer	4.89e-05	0.000394	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HSPB1—hematologic cancer	4.89e-05	0.000394	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CCL3—hematologic cancer	4.89e-05	0.000394	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PTHLH—hematologic cancer	4.84e-05	0.000389	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—SDC1—hematologic cancer	4.84e-05	0.000389	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—IL2RA—hematologic cancer	4.76e-05	0.000383	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PTGER4—hematologic cancer	4.71e-05	0.000379	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—LCK—hematologic cancer	4.68e-05	0.000377	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—H3F3A—hematologic cancer	4.59e-05	0.00037	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PRKCZ—hematologic cancer	4.46e-05	0.000359	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CG—hematologic cancer	4.36e-05	0.000351	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PARP1—hematologic cancer	4.31e-05	0.000347	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FBXW7—hematologic cancer	4.24e-05	0.000341	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HDAC2—hematologic cancer	4.16e-05	0.000335	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CXCR4—hematologic cancer	4.16e-05	0.000335	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CBL—hematologic cancer	4.05e-05	0.000326	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL3—hematologic cancer	4.01e-05	0.000323	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CG—hematologic cancer	3.96e-05	0.000319	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PTPN1—hematologic cancer	3.94e-05	0.000317	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PTPN11—hematologic cancer	3.89e-05	0.000313	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—RASGRP1—hematologic cancer	3.88e-05	0.000312	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—SYK—hematologic cancer	3.87e-05	0.000311	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HSP90AA1—hematologic cancer	3.87e-05	0.000311	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CD—hematologic cancer	3.83e-05	0.000309	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CREB1—hematologic cancer	3.77e-05	0.000304	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—STAT1—hematologic cancer	3.73e-05	0.0003	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—CCL2—hematologic cancer	3.69e-05	0.000297	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—IL6R—hematologic cancer	3.68e-05	0.000296	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	3.62e-05	0.000291	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—JAK2—hematologic cancer	3.52e-05	0.000283	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—MAP2K1—hematologic cancer	3.51e-05	0.000282	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—GRB2—hematologic cancer	3.49e-05	0.000281	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CD—hematologic cancer	3.48e-05	0.00028	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PDGFA—hematologic cancer	3.48e-05	0.00028	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—KITLG—hematologic cancer	3.43e-05	0.000276	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—STAT5A—hematologic cancer	3.35e-05	0.00027	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	3.34e-05	0.000269	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CDKN2B—hematologic cancer	3.32e-05	0.000267	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3R1—hematologic cancer	3.29e-05	0.000265	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CD86—hematologic cancer	3.21e-05	0.000259	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—JAK2—hematologic cancer	3.2e-05	0.000257	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HES1—hematologic cancer	3.17e-05	0.000255	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—NCOR1—hematologic cancer	3.15e-05	0.000254	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CSF2—hematologic cancer	3.12e-05	0.000251	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FGF1—hematologic cancer	3.12e-05	0.000251	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FOXO1—hematologic cancer	3.07e-05	0.000247	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—IL2—hematologic cancer	3.07e-05	0.000247	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PDGFRB—hematologic cancer	3.07e-05	0.000247	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CB—hematologic cancer	3.04e-05	0.000244	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PDGFRA—hematologic cancer	3.02e-05	0.000243	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—JAK1—hematologic cancer	3.01e-05	0.000242	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PRKCG—hematologic cancer	3.01e-05	0.000242	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL2RA—hematologic cancer	2.81e-05	0.000226	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—IL2—hematologic cancer	2.79e-05	0.000224	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TERT—hematologic cancer	2.78e-05	0.000224	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PDGFB—hematologic cancer	2.71e-05	0.000218	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TSC2—hematologic cancer	2.65e-05	0.000213	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FGFR3—hematologic cancer	2.55e-05	0.000205	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MAPK14—hematologic cancer	2.52e-05	0.000203	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ESR1—hematologic cancer	2.48e-05	0.000199	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FN1—hematologic cancer	2.45e-05	0.000197	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—NFKBIA—hematologic cancer	2.42e-05	0.000194	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—BAD—hematologic cancer	2.42e-05	0.000194	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—NOTCH1—hematologic cancer	2.39e-05	0.000193	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CD80—hematologic cancer	2.34e-05	0.000189	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—KIT—hematologic cancer	2.34e-05	0.000188	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CG—hematologic cancer	2.34e-05	0.000188	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—NRAS—hematologic cancer	2.34e-05	0.000188	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PTPN11—hematologic cancer	2.3e-05	0.000185	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—MAPK3—hematologic cancer	2.24e-05	0.00018	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CREB1—hematologic cancer	2.23e-05	0.000179	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—BRAF—hematologic cancer	2.2e-05	0.000177	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CCL2—hematologic cancer	2.18e-05	0.000175	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL6R—hematologic cancer	2.17e-05	0.000175	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CREBBP—hematologic cancer	2.17e-05	0.000175	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MAP2K1—hematologic cancer	2.07e-05	0.000167	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CD—hematologic cancer	2.06e-05	0.000166	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.04e-05	0.000164	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—KRAS—hematologic cancer	2.01e-05	0.000162	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—FGF2—hematologic cancer	1.97e-05	0.000159	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3R1—hematologic cancer	1.94e-05	0.000156	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—JAK2—hematologic cancer	1.89e-05	0.000152	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CA—hematologic cancer	1.85e-05	0.000149	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MDM2—hematologic cancer	1.84e-05	0.000148	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CB—hematologic cancer	1.79e-05	0.000144	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MTOR—hematologic cancer	1.79e-05	0.000144	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—HRAS—hematologic cancer	1.71e-05	0.000138	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CDKN1B—hematologic cancer	1.68e-05	0.000135	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—AKT1—hematologic cancer	1.66e-05	0.000134	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CASP3—hematologic cancer	1.65e-05	0.000133	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL2—hematologic cancer	1.65e-05	0.000133	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—IL6—hematologic cancer	1.64e-05	0.000132	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CCND1—hematologic cancer	1.61e-05	0.000129	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—JUN—hematologic cancer	1.6e-05	0.000129	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CDKN1A—hematologic cancer	1.55e-05	0.000125	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PTEN—hematologic cancer	1.55e-05	0.000125	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MAPK8—hematologic cancer	1.52e-05	0.000122	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—AKT1—hematologic cancer	1.51e-05	0.000122	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—EP300—hematologic cancer	1.48e-05	0.000119	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—SRC—hematologic cancer	1.44e-05	0.000116	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—VEGFA—hematologic cancer	1.4e-05	0.000113	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—STAT3—hematologic cancer	1.39e-05	0.000112	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—NRAS—hematologic cancer	1.38e-05	0.000111	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MAPK3—hematologic cancer	1.32e-05	0.000107	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MYC—hematologic cancer	1.29e-05	0.000104	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TGFB1—hematologic cancer	1.28e-05	0.000103	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—KRAS—hematologic cancer	1.19e-05	9.58e-05	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CA—hematologic cancer	1.09e-05	8.8e-05	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TP53—hematologic cancer	1.06e-05	8.51e-05	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HRAS—hematologic cancer	1.01e-05	8.14e-05	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL6—hematologic cancer	9.68e-06	7.79e-05	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—AKT1—hematologic cancer	8.93e-06	7.19e-05	CbGpPWpGaD
